- Home
- HHS vs CTXR Comparison
HHS vs CTXR Comparison
Compare HHS & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HHS | CTXR |
|---|---|---|
| Founded | 1923 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.2M | 18.9M |
| IPO Year | 1994 | 2010 |
Fundamental Metrics
Financial Performance| Metric | HHS | CTXR |
|---|---|---|
| Price | $2.53 | $0.54 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 3.9K | ★ 612.5K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 97.35 | 43.38 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $159,570,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $147.57 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.22 | $0.48 |
| 52 Week High | $5.39 | $2.24 |
Technical Indicators
Market Signals| Indicator | HHS | CTXR |
|---|---|---|
| Relative Strength Index (RSI) | 43.48 | 39.91 |
| Support Level | $2.33 | $0.48 |
| Resistance Level | $2.89 | $0.74 |
| Average True Range (ATR) | 0.04 | 0.05 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 28.61 | 3.66 |
Price Performance
Historical ComparisonAbout HHS Harte-Hanks Inc.
Harte-Hanks Inc is a customer experience company. The Company operates three business segments: Marketing Services; Customer Care; and Fulfillment & Logistics Services. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.
About CTXR Citius Pharmaceuticals Inc.
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.